Cargando…

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease

INTRODUCTION: People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. METHODS: Noradrenaline, adrenaline, and their metabolite 3-methoxy-4-hydroxyphen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dekker, Alain D., Vermeiren, Yannick, Carmona-Iragui, Maria, Benejam, Bessy, Videla, Laura, Gelpi, Ellen, Aerts, Tony, Van Dam, Debby, Fernández, Susana, Lleó, Alberto, Videla, Sebastian, Sieben, Anne, Martin, Jean-Jacques, Blesa, Rafael, Fortea, Juan, De Deyn, Peter P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	CSF Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956808/ https://www.ncbi.nlm.nih.gov/pubmed/29780859 http://dx.doi.org/10.1016/j.dadm.2017.11.001

Ejemplares similares

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
por: Marelli, Cecilia, et al.
Publicado: (2015)

The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease
por: Vermeiren, Yannick, et al.
Publicado: (2015)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests
por: Benejam, Bessy, et al.
Publicado: (2020)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Consensus guidelines for lumbar puncture in patients with neurological diseases
por: Engelborghs, Sebastiaan, et al.
Publicado: (2017)

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease
por: Benejam, Bessy, et al.
Publicado: (2022)

Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome
por: Videla, Laura, et al.
Publicado: (2022)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
por: Toombs, Jamie, et al.
Publicado: (2018)

Cerebrospinal fluid collection: An informative animation video for patients and caregivers
por: Babapour Mofrad, R., et al.
Publicado: (2019)

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
por: Düzel, Emrah, et al.
Publicado: (2018)

Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
por: Koch, Manja, et al.
Publicado: (2017)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome
por: Belbin, Olivia, et al.
Publicado: (2020)

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome
por: Kamer, Angela R., et al.
Publicado: (2016)

Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
por: Iulita, Maria Florencia, et al.
Publicado: (2022)

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study
por: Pegueroles, Jordi, et al.
Publicado: (2018)

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
por: Fortea, Juan, et al.
Publicado: (2020)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease
por: Jimenez, Amanda, et al.
Publicado: (2017)

Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
por: Van Dam, Debby, et al.
Publicado: (2016)

Evaluation of biochemical and hematological parameters in adults with Down syndrome
por: de Gonzalo-Calvo, David, et al.
Publicado: (2020)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome
por: Iulita, M Florencia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f2f9d5ftv9n7d1h4g5r95qsmpl